EUCTR2005-001008-37-SE进行中（未招募）不适用
Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody
Sahlgrenska University Hospital0 个研究点目标入组 100 人开始时间: 2005年3月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Multiple sclerosis patients aged 18-65 years treated by Rebif 22 microgram/dose for more than 1 year.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Insufficient patient compliance.
研究者
相似试验
已完成
Unknown
Changes in specific antibody titers and interferon gamma levels after a BNT162b2 vaccine boosterCOVID-19JPRN-UMIN000048810Fukuoka City Hospital400
已完成
不适用
Changes in specific antibody titers and interferon gamma levels after an Omicron BA.4/BA.5-Adapted Bivalent BoosterCOVID-19JPRN-UMIN000049273Fukuoka City Hospital150
已完成
不适用
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adultsSystemic lupus erythematosusJPRN-UMIN000008987Chugai Pharmaceutical co., ltd.110
已完成
不适用
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adultsSystemic lupus erythematosusJPRN-UMIN000009040Chugai Pharmaceutical co., ltd.110
已完成
不适用
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adultsSystemic lupus erythematosusJPRN-UMIN000008787Chugai Pharmaceutical co., ltd.110